


Accepted Manuscript

Management of Hepatitis B: My Practice and how it relates to the Guidelines

Suna Yapali, Nizar Talaat, Anna S. Lok



PII: S1542-3565(13)00606-X

DOI: [10.1016/j.cgh.2013.04.036](https://doi.org/10.1016/j.cgh.2013.04.036)

Reference: YJCGH 53310

To appear in: *Clinical Gastroenterology and Hepatology*

Received Date: 2 April 2013

Revised Date: 16 April 2013

Accepted Date: 17 April 2013

Please cite this article as: Yapali S, Talaat N, Lok AS, Management of Hepatitis B: My Practice and how it relates to the Guidelines, *Clinical Gastroenterology and Hepatology* (2013), doi: 10.1016/j.cgh.2013.04.036.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Clinical Gastroenterology and Hepatology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

Management of Hepatitis B: My Practice and how it relates to the Guidelines

Short title: Hepatitis B management in clinical practice

Suna Yapali, Nizar Talaat, Anna S. Lok

Division of Gastroenterology and Hepatology,

University of Michigan Health System, Ann Arbor, Michigan, USA

Grant support: Suna Yapali received support from Turkish Association for The Study of the Liver. The Tuktawa Foundation through the Alice Lohrman Andrews Professorship provided support for Suna Yapali, Nizar Talaat and Anna S. Lok.

Abbreviations: AASLD, American Association for the Study of Liver Disease; ALT, Alanine aminotransferase; anti-HBc, hepatitis B core antibody; APASL, Asian Pacific Association for the Study of the Liver; APRI, Aspartate-aminotransferase-platelet-ratio index; CHB, Chronic hepatitis B; EASL, European Association for the Study of the Liver; HBV, Hepatitis B virus; HBeAg, Hepatitis B e antigen; HBsAg, Hepatitis B surface antigen; HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus; HDV, Hepatitis D virus; HIV, Human immunodeficiency virus; IFN, interferon; NUC, Nucleos(t)ide analogues; PEG-IFN, pegylated-interferon; TSH, Thyroid stimulating hormone; ULN, upper limit of normal

Correspondence: Anna S. Lok, MD, Division of Gastroenterology, University of Michigan Health System, 3912 Taubmann Center, SPC 5362, Ann Arbor, MI 48109, USA. Fax: +17349367392; e-mail: aslok@umich.edu

Disclosures: Suna Yapali and Nizar Talaat have nothing to disclose. Anna S. Lok had received research grants from Bristol-Myers Squibb, Gilead Sciences, and Merck and had served on advisory board for Gilead Sciences, GlaxoSmithKline, Merck and Roche.

Author Contributions: S. Yapali, N. Talaat contributed to the literature review, research, discussion and drafting of this manuscript; A. S. Lok contributed to the research, discussion, and editing of this manuscript.

Download English Version:

<https://daneshyari.com/en/article/3281991>

Download Persian Version:

<https://daneshyari.com/article/3281991>

[Daneshyari.com](https://daneshyari.com)